Filtered By:
Condition: Disability
Therapy: Stem Cell Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 293 results found since Jan 2013.
Comparative Analysis of the Results of Stroke Treatment With Multiple Administrations of Wharton's Jelly Mesenchymal Stem Cells-Derived HE-ATMP and Standard Conservative Treatment: Case Series Study
Cell Transplant. 2023 Jan-Dec;32:9636897231195145. doi: 10.1177/09636897231195145.ABSTRACTStroke remains still the leading cause of long-term disability worldwide. Although interventions such as early reperfusion, intravenous thrombolysis, and endovascular revascularization have shown neurological benefit in stroke patients, there is still lack of effective treatment enabling regeneration of nervous tissue after cerebral ischemic episodes. Cell therapy is an evolving opportunity for stroke survivors with residual neurological deficits. The purpose of this study was to evaluate safety and potential efficacy of multiple admi...
Source: Cell Transplantation - August 30, 2023 Category: Cytology Authors: Olga Milczarek Jakub Swad źba Patrycja Swad źba Anna Starowicz-Filip Roger M Krzy żewski Stanis ław Kwiatkowski Marcin Majka Source Type: research
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Bone marrow mesenchymal stem cell-derived exosomal miR-193b-5p reduces pyroptosis after ischemic stroke by targeting AIM2
Ischemic stroke is a frequently occurring cerebrovascular disease (CVD) linked to high mortality, disability, and incidence rates, and the second factor causing global mortality41,3. There are two common sources of embolism in ischamic strokes: large artery atherosclerosis and small artery atherosclerosis. Ischemic stroke can be treated clinically with thrombolytic therapy4. Although ischemic stroke is treatable, post-cerebral ischemia blood reperfusion frequently induces inflammation, oxidative stress (OS) or additional unfavorable events that may exacerbate brain injury20,24.
Source: Journal of Stroke and Cerebrovascular Diseases - June 30, 2023 Category: Neurology Authors: Yingju Wang, Hongping Chen, Xuehui Fan, Chen Xu, Meng Li, Hongxue Sun, Jihe Song, Feihong Jia, Wan Wei, Fangchao Jiang, Guozhong Li, Di Zhong Source Type: research
Oxygen –Glucose Deprived Peripheral Blood Mononuclear Cells Protect Against Ischemic Stroke
AbstractStroke is the leading cause of severe long-term disability. Cell therapy has recently emerged as an approach to facilitate functional recovery in stroke. Although administration of peripheral blood mononuclear cells preconditioned by oxygen –glucose deprivation (OGD-PBMCs) has been shown to be a therapeutic strategy for ischemic stroke, the recovery mechanisms remain largely unknown. We hypothesised that cell–cell communications within PBMCs and between PBMCs and resident cells are necessary for a polarising protective phenotype. H ere, we investigated the therapeutic mechanisms underlying the effects of OGD-PB...
Source: Neurotherapeutics - June 19, 2023 Category: Neurology Source Type: research
Functional reconstruction of the impaired cortex and motor function by hMGEOs transplantation in stroke
Biochem Biophys Res Commun. 2023 Jun 3;671:87-95. doi: 10.1016/j.bbrc.2023.06.010. Online ahead of print.ABSTRACTStroke is the leading cause of death and long-term disability worldwide. But treatments are not available to promote functional recovery, and efficient therapies need to be investigated. Stem cell-based therapies hold great promise as potential technologies to restore function in brain disorders. Loss of GABAergic interneurons after stroke may result in sensorimotor defects. Here, by transplanting human brain organoids resembling the MGE domain (human MGE organoids, hMGEOs) derived from human induced pluripotent...
Source: Cell Research - June 10, 2023 Category: Cytology Authors: Shi-Ying Cao Meng-Dan Tao Shu-Ning Lou Di Yang Yu-Hui Lin Hai-Yin Wu Lei Chang Chun-Xia Luo Yun Xu Yan Liu Dong-Ya Zhu Source Type: research
Bone Marrow Mesenchymal Stem Cell-Derived Exosomal KLF4 Alleviated Ischemic Stroke Through Inhibiting N6-Methyladenosine Modification Level of Drp1 by Targeting lncRNA-ZFAS1
AbstractIschemic stroke has become a serious public health problem that causes high rates of death and disability. Bone marrow mesenchymal stem cell (BMSC)-derived exosomes have shown promising therapeutic results in IS, while the underlying mechanisms need further investigation. Cell and mice models were established through oxygen–glucose deprivation/reoxygenation (OGD/R) treatment and middle cerebral artery occlusion (MCAO)/reperfusion. Exosomes were isolated from BMSCs. Related gene and protein expression was measured by qRT-PCR, Western blotting, and immunofluorescence analysis. The biological functions of treate d...
Source: Molecular Neurobiology - May 28, 2023 Category: Neurology Source Type: research
From lift off to splash down: An update on Mayo Clinic stem cells in space
It's been six years since Mayo Clinic physician Abba Zubair, M.D., Ph.D., watched stem cells from his regenerative medicine laboratory blast into space as part of a research effort to see if zero gravity would help the cells multiply faster. Approximately 15 million people worldwide experience a stroke annually, according to the World Health Organization. Currently, stroke remains a top cause of death and disability in the world. Finding new therapies for stroke is important…
Source: Mayo Clinic Florida News - May 26, 2023 Category: Hospital Management Source Type: news
Mitochondrial transplantation and immune response of human bone marrow mesenchymal stem cells for the Therapeutic of ischemic stroke
Curr Stem Cell Res Ther. 2023 May 5. doi: 10.2174/1574888X18666230505103407. Online ahead of print.ABSTRACTIschemic stroke is the leading cause of death and disability worldwide, with increasing incidence and mortality, imposing a significant social and economic burden on patients and their families. However, cerebral vascular occlusion leads to acute loss of neurons and destruction of synaptic structures. The limited treatment options cannot adequately address intra-neuronal mitochondrial dysfunction due to stroke. Therefore, stem cell-derived mitochondria transplantation plays an important role in neuronal protection and...
Source: Current Stem Cell Research and Therapy - May 8, 2023 Category: Stem Cells Authors: Yidong Liao Jiang Ming Wenxue Song Guangtang Chen Junshuan Cui Longcai He Zili Wang Xudong Wang Mingsong Xiong Hua Yang Kaya Xu Source Type: research
